Design and discovery of small molecules targeting raf-1 kinase.

Curr Pharm Des

Bayer Research Center, Bayer Corporation, Pharmaceutical Division, 400 Morgan Lane, West Haven, CT 06516, USA.

Published: March 2003


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Raf kinase, an enzyme which acts downstream in the Ras signaling pathway, is involved in cancerous cell proliferation. Thus, small molecule inhibitors of Raf kinase activity may be important agents for the treatment of cancer. A novel class of Raf-1 inhibitors was discovered, using a combination of medicinal and combinatorial chemistry approaches. This effort culminated in the identification of the clinical candidate BAY 43-9006, currently undergoing Phase I clinical trials. The present review summarizes the medicinal chemistry development of ureas as highly potent inhibitors of Raf-1 kinase.

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612023393125DOI Listing

Publication Analysis

Top Keywords

raf-1 kinase
8
raf kinase
8
design discovery
4
discovery small
4
small molecules
4
molecules targeting
4
targeting raf-1
4
kinase
4
kinase raf
4
kinase enzyme
4

Similar Publications

Background: Mediator complex subunit 10 (MED10) serves as a critical regulator of eukaryotic gene expression by facilitating RNA polymerase II activity. Our investigation aims to characterize MED10's functional contributions and underlying molecular pathways in hepatocellular carcinoma (HCC) development.

Methods: MED10 expression patterns in HCC and their correlation with clinicopathological parameters and patient outcomes were examined using bioinformatics databases and immunohistochemistry.

View Article and Find Full Text PDF

CRAF (RAF1) is one of three RAF-family kinases that initiate MAP kinase signaling in response to activated RAS and is essential for oncogenic signaling from mutant KRAS. Like BRAF, CRAF is regulated by 14-3-3 engagement and by intramolecular autoinhibitory interactions of its N-terminal regulatory region. Unlike BRAF, it is thought to require tyrosine phosphorylation in its N-terminal acidic (NtA) motif for full catalytic activation.

View Article and Find Full Text PDF

Tanshinone VI Induces Cardiac Differentiation of Cardiosphere-Derived Cells Prepared from Rat Hearts.

Biol Pharm Bull

August 2025

Department of Molecular and Cellular Pharmacology, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan.

Cell transplantation therapy is a promising new treatment for myocardial infarction and heart failure. Developing methods to promote the engraftment of cardiac stem cells into cardiac tissue and their differentiation into cardiac cells is a strategy for improving the efficacy of cell transplantation therapy. Tanshinone VI (TanVI), a component extracted from the roots of Salvia miltiorrhiza Bunge (Labiatae), is a possible pharmacological agent for ischemic heart disease.

View Article and Find Full Text PDF

The lymphatic system, a complex physiological network of lymphatic organs and vessels, is essential for maintaining fluid homeostasis. Dysfunction of lymphatic system can lead to lymphedema, a pathology characterized by the accumulation of interstitial fluid in peripheral tissues. This study aimed to identify novel genetic variants in genes within the RAS/ MAPK pathway and assess their potential association with lymphedema onset.

View Article and Find Full Text PDF